Buscar en
Neurología
Toda la web
Inicio Neurología Concomitant treatment with safinamide and antidepressant drugs: Safety data from...
Journal Information

Statistics

Follow this link to access the full text of the article

Original article
Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice
Tratamiento concomitante de safinamida y antidepresivos: Datos de seguridad sobre la práctica en la vida real
P. Pérez-Torrea,
Corresponding author
paulaptorre@gmail.com

Corresponding author.
, J.L. López-Sendóna, V. Mañanes Barralb, I. Pareesa, S. Fanjul-Arbósa, E. Monreala, A. Alonso-Canovasa, J.C. Martínez Castrilloa
a Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain
b Neuropsychology, Movement Disorders Unit, Neurology Department, IRYCIS, Hospital Ramón y Cajal, Madrid, Spain
Read
2167
Times
was read the article
569
Total PDF
1598
Total HTML
Share statistics
Article information
ISSN: 02134853
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 April 96 12 108
2024 March 69 24 93
2024 February 81 47 128
2024 January 95 54 149
2023 December 63 42 105
2023 November 81 21 102
2023 October 94 9 103
2023 September 72 15 87
2023 August 39 11 50
2023 July 60 11 71
2023 June 57 17 74
2023 May 79 14 93
2023 April 74 9 83
2023 March 37 7 44
2023 February 39 16 55
2023 January 31 5 36
2022 December 29 4 33
2022 November 44 33 77
2022 October 26 10 36
2022 September 49 13 62
2022 August 26 7 33
2022 July 30 10 40
2022 June 27 8 35
2022 May 39 12 51
2022 April 49 13 62
2022 March 50 24 74
2022 February 33 12 45
2022 January 36 15 51
2021 December 36 19 55
2021 November 35 18 53
2021 October 16 20 36
2021 September 6 37 43
Show all

Follow this link to access the full text of the article

es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos